References
- Taubenberger JK, Reid AH, Lourens RM et al. Characterization of the 1918 influenza virus polymerase genes. Nature437, 889–893 (2005).
- Ungchusak K, Auewarakul P, Dowell SF et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med.352, 333–340 (2005).
- Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet371, 1464–1475 (2008).
- Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine20, 3068–3087 (2002).
- Nichol KL, Lind A, Margolis KL et al. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med.333, 889–893 (1995).
- Nichol KL, Nordin J, Mullooly J et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N. Engl. J. Med.348, 1322–1332 (2003).
- Emanuel EJ, Wertheimer A. Public health. Who should get influenza vaccine when not all can? Science312, 854–855 (2006).
- Audsley JM, Tannock GA. Cell-based influenza vaccines: progress to date. Drugs68, 1483–1491 (2008).
- Horimoto T, Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol. Med.12, 506–514 (2006).
- Smith KA, Colvin CJ, Weber PS, Spatz SJ, Coussens PM. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine26, 3778–3782 (2008).
- Morenweiser R. Downstream processing of viral vectors and vaccines. Gene Ther.12, S103–S110 (2005).
- Tang DC, Van Kampen KR. Toward the development of vectored vaccines in compliance with evolutionary medicine. Expert Rev. Vaccines7, 399–402 (2008).
- Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol.7, 267–278 (2007).
- Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis.191, 1210–1215 (2005).
- Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354, 1343–1351 (2006).
- Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet367, 1657–1664 (2006).
- Keitel WA, Campbell JD, Treanor JJ et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a Phase I–II randomized clinical trial. J. Infect. Dis.198, 1309–1316 (2008).
- Ozaki H, Govorkova EA, Li C et al. Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J. Virol.78, 1851–1857 (2004).
- Palese P. Making better influenza virus vaccines? Emerg. Infect. Dis.12, 61–65 (2006).
- Pau MG, Ophorst C, Koldijk MH et al. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine19, 2716–2721 (2001).
- Lee CW, Jung K, Jadhao SJ, Suarez DL. Evaluation of chicken-origin (DF-1) and quail-origin (QT-6) fibroblast cell lines for replication of avian influenza viruses. J. Virol. Methods153, 22–28 (2008).
- Horimoto T, Takada A, Fujii K et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine24, 3669–3676 (2006).
- Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science259, 1745–1748 (1993).
- Fynan EF, Webster RG, Fuller DH et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl Acad. Sci. USA90, 11478–11482 (1993).
- Chen MW, Cheng TJ, Huang Y et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl Acad. Sci. USA105, 13538–13543 (2008).
- Cox MM. Progress on baculovirus-derived influenza vaccines. Curr. Opin. Mol. Ther.10, 56–61 (2008).
- Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE3, e1501 (2008).
- Mahmood K, Bright RA, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine26, 5393–5399 (2008).
- Treanor JJ, Schiff GM, Hayden FG et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA297, 1577–1582 (2007).
- Kreijtz JH, Suezer Y, de Mutsert G et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J. Infect. Dis.199, 405–413 (2009).
- Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine23, 1029–1036 (2005).
- Gao W, Soloff AC, Lu X et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol.80, 1959–1964 (2006).
- Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet367, 475–481 (2006).
- Toro H, Tang DC, Suarez DL et al. Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector. Vaccine25, 2886–2891 (2007).
- Toro H, Tang DC, Suarez DL, Zhang J, Shi Z. Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine. Vaccine26, 2640–2646 (2008).
- Avakian AP, Poston RM, Kong FK, Van Kampen KR, Tang DC. Automated mass immunization of poultry: the prospect for nonreplicating human adenovirus-vectored in ovo vaccines. Expert Rev. Vaccines6, 457–465 (2007).
- Holman DH, Wang D, Raja NU et al. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine26, 2627–2639 (2008).
- Sykes K. Progress in the development of genetic immunization. Expert Rev. Vaccines7(9), 1395–1404 (2008).
- Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines7(2), 175–191 (2008).
- Shi Z, Zeng M, Yang G et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J. Virol.75, 11474–11482 (2001).
- Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet372, 1881–1893 (2008).
- Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science275, 1320–1323 (1997).
- Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment. Cell73, 309–319 (1993).
- Shayakhmetov DM, Eberly AM, Li ZY, Lieber A. Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J. Virol.79, 1053–1061 (2005).
- Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J. Virol.79, 1992–2000 (2005).
- Greber UF, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell75, 477–486 (1993).
- Leopold PL, Crystal RG. Intracellular trafficking of adenovirus: many means to many ends. Adv. Drug Deliv. Rev.59, 810–821 (2007).
- McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis. Lancet372, 1894–1905 (2008).
- Hoelscher MA, Jayashankar L, Garg S et al. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin. Pharmacol. Ther.82, 665–671 (2007).
- Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res.132, 1–14 (2008).
- Tang DC, Johnston SA, Carbone DP. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther.1, 15–20 (1994).
- Tang DC, Jennelle RS, Shi Z et al. Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. Hum. Gene Ther.8, 2117–2124 (1997).
- Yang Y, Nunes FA, Berencsi K et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl Acad. Sci. USA91, 4407–4411 (1994).
- Nwanegbo E, Vardas E, Gao W et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol.11, 351–357 (2004).
- Swain SL, Hu H, Huston G. Class II-independent generation of CD4 memory T cells from effectors. Science286, 1381–1383 (1999).
- Molinier-Frenkel V, Lengagne R, Gaden F et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol.76, 127–135 (2002).
- Tucker SN, Tingley DW, Scallan CD. Oral adenoviral-based vaccines: historical perspective and future opportunity. Expert Rev. Vaccines7, 25–31 (2008).
- Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy. N. Engl. J. Med.350, 860–861 (2004).
- Croyle MA, Patel A, Tran KN et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE3, e3548 (2008).
- Zabner J, Petersen DM, Puga AP et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat. Genet.6, 75–83 (1994).
- Wadsworth SC, Zhou H, Smith AE, Kaplan JM. Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J. Virol.71, 5189–5196 (1997).
- Scaria A, St. George JA, Jiang C et al. Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium. J. Virol.72, 7302–7309 (1998).
- Chen P, Kovesdi I, Bruder JT. Effective repeat administration with adenovirus vectors to the muscle. Gene Ther.7, 587–595 (2000).
- Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med.356, 685–696 (2007).
- Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine18, 899–906 (1999).
- Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol.173, 6357–6365 (2004).
- Lemiale F, Kong WP, Akyurek LM et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol.77, 10078–10087 (2003).
- Betts RF, Treanor JJ. Approaches to improved influenza vaccination. Vaccine18, 1690–1695 (2000).
- Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine25, 3871–3878 (2007).
- Toovey S. Influenza-associated central nervous system dysfunction: a literature review. Travel Med. Infect. Dis.6, 114–124 (2008).
- Thomas CE, Edwards P, Wickham TJ, Castro MG, Lowenstein PR. Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J. Virol.76, 3452–3460 (2002).
- Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol.36, 59–74 (1977).
- Fallaux FJ, Bout A, van der Velde I et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther.9, 1909–1917 (1998).
- Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol. Biotechnol.3, 207–220 (1995).
- Zhu J, Grace M, Casale J et al. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. Hum. Gene Ther.10, 113–121 (1999).
- Lochmuller H, Jani A, Huard J et al. Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (δ E1 + δ E3) during multiple passages in 293 cells. Hum. Gene Ther.5, 1485–1491 (1994).
- Murakami P, Havenga M, Fawaz F et al. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. J. Virol.78, 6200–6208 (2004).
- Chartier C, Degryse E, Gantzer M et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol.70, 4805–4810 (1996).
- He TC, Zhou S, da Costa LT et al. A simplified system for generating recombinant adenoviruses. Proc. Natl Acad. Sci. USA95, 2509–2514 (1998).
- Zeng M, Smith SK, Siegel F et al. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques31, 260–262 (2001).
- Babiss LE, Vales LD. Promoter of the adenovirus polypeptide IX gene: similarity to E1B and inactivation by substitution of the simian virus 40 TATA element. J. Virol.65, 598–605 (1991).
- Parks RJ. Adenovirus protein IX: a new look at an old protein. Mol. Ther.11, 19–25 (2005).
- Rosa-Calatrava M, Grave L, Puvion-Dutilleul F, Chatton B, Kedinger C. Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. J. Virol.75, 7131–7141 (2001).
- Vellinga J, Van der Heijdt S, Hoeben RC. The adenovirus capsid: major progress in minor proteins. J. Gen. Virol.86, 1581–1588 (2005).
- Maranga L, Aunins JG, Zhou W. Characterization of changes in PER.C6 cellular metabolism during growth and propagation of a replication-deficient adenovirus vector. Biotechnol. Bioeng.90, 645–655 (2005).
- Perkins S. Selection and optimization of anion exchange resins for purification of type 5 adenovirus. Presented at: Viral Vectors and Vaccines Conference. Southampton, Bermuda, 6–8 November 2006.
- Evans RK, Nawrocki DK, Isopi LA et al. Development of stable liquid formulations for adenovirus-based vaccines. J. Pharm. Sci.93, 2458–2475 (2004).
- Swayne DE, Kapczynski D. Strategies and challenges for eliciting immunity against avian influenza virus in birds. Immunol. Rev.225, 314–331 (2008).
- van Ginkel FW, Tang DC, Gulley SL, Toro H. Induction of mucosal immunity in the avian Harderian gland with a replication-deficient Ad5 vector expressing avian influenza H5 hemagglutinin. Dev. Comp. Immunol.33, 28–34 (2009).
- Kowalczyk K, Daiss J, Halpern J, Roth TF. Quantitation of maternal–fetal IgG transport in the chicken. Immunology54, 755–762 (1985).
- Mast J, Gilson D, Morales D, Meulemans G, van den Berg TP. Transfer of material antibodies from the yolk sac to the chicken. In: Immunosuppressive Viral Diseases in Poultry, Annual Report and Proceedings 2001. van den Berg TP (Ed.). Office for Official Publications of the European Communities, Luxembourg 180–183 (2003).
Website
- US FDA www.fda.gov